medigraphic.com
ISSN 2594-3006 (Digital)
ISSN 2007-1752 (Impreso)
Archivos de Medicina de Urgencia de México

2025, Número 1

<< Anterior

Arch Med Urg Mex 2025; 17 (1)


Recomendaciones de terapia de alto flujo de oxígeno en el servicio de urgencias PARTE 2

Sanabría-Cordero D, Trejo-Rosas S, Mendez-Jesus IA, Mendoza-Portillo E, Russi Hernández M

Idioma: Español
Referencias bibliográficas: 35
Paginas: 58-68
Archivo PDF: 965.06 Kb.


RESUMEN

El abordaje de la insuficiencia respiratoria aguda es una emergencia en cualquier unidad hospitalaria ya que el inicio temprano o tardío de su tratamiento tendrá un impacto importante en el pronóstico de los pacientes, por tal motivo se realizó una revisión del uso de terapia de alto flujo de oxígeno (TAFO) en diferentes escenarios clínicos; en el presente artículo se abordara la insuficiencia respiratoria aguda tipo 1 o hipoxemica (IRA tipo 1), insuficiencia respiratoria aguda tipo 2 o hipercápnica (IRA tipo 2) y los diferentes algoritmos de apoyo de oxigeno por medio de cánulas nasales de alto flujo (CNAF) en pacientes postextubación y postquirúrgicos que requieren de TAFO.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Nishimura M. High-flow nasal cannula oxygen therapy in adults:physiological benefits, indication, clinical benefits, and adverseeffects. Respir Care. 2016;61(4):529-541.

  2. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinicalimplications. Chest. 2015;148(1):253-261.

  3. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasalcannula in acute hypoxemic respiratory failure. N Engl J Med.2015;372(23):2185-2196.

  4. Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapyin acute respiratory failure. Respir Care. 2010;55(4):408-413.

  5. Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidifiedhigh flow nasal oxygen in critical care patients: a prospectivepilot study. Intensive Care Med. 2011;37(11):1780-1786.

  6. Lee MK, Choi J, Park B, et al. High-flow nasal cannula therapyin acute hypoxemic respiratory failure: a randomized clinicaltrial. Respir Care. 2016;61(3):291-299.

  7. Maggiore SM, Idone FA, Vaschetto R, et al. Nasal high-flow versusVenturi mask oxygen therapy after extubation. Am J Respir CritCare Med. 2014;190(3):282-288.

  8. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure.Lancet. 2009;374(9685):250-259.

  9. Pisani L, Vega ML. Use of nasal high flow in stable COPD: rationaleand physiology. COPD. 2017;14(3):346-350.

  10. Cortegiani A, Longhini F, Madotto F, et al. High flow nasal therapyversus conventional oxygen therapy in patients with acute respiratoryfailure: a systematic review and meta-analysis. J Crit Care.2019;50:197-204.

  11. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns ofCare, and Mortality for Patients With Acute Respiratory DistressSyndrome in Intensive Care Units in 50 Countries. JAMA.2016;315(8):788–800.

  12. Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009pandemic influenza A virus and bacterial coinfection in the UnitedStates. Crit Care Med. 2012;40(5):1487–1498.

  13. Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acuterespiratory distress syndrome: is a different approach to managementwarranted? Lancet Respir Med. 2020;8(8):816–821.

  14. Roca O, Messika J, Caralt B, et al. Predicting success of high-flownasal cannula in pneumonia patients with hypoxemic respiratoryfailure: The utility of the ROX index. J Crit Care. 2016;35:200–205.

  15. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasalcannula in acute hypoxemic respiratory failure. N Engl J Med.2015;372(23):2185–2196.

  16. Prakash J, Bhattacharya PK, Singh N, et al. Usefulness of ROXindex in prediction of need for invasive mechanical ventilation inpatients with COVID-19 pneumonia. J Anaesthesiol Clin Pharmacol.2021;37(1):88–93.

  17. (***) Bos LD, Artigas A, Constantin J-M, et al. Precision medicinein acute respiratory distress syndrome: workshop report andrecommendations for future research. Eur Respir Rev 2021; 30:200317.

  18. Bell N, Hutchinson CL, Green TC, et al. Randomised control trialof humidified high flow nasal cannulae versus standard oxygenin the emergency department. Emerg Med Australas 2015; 27:537–541.

  19. Lemiale V, Mokart D, Mayaux J, et al. The effects of a 2-h trial ofhigh-flow oxygen by nasal cannula versus Venturi mask in immunocompromisedpatients with hypoxemic acute respiratory failure:a multicenter randomized trial. Crit Care 2015; 19: 380.

  20. Rittayamai N, Tscheikuna J, Praphruetkit N, et al. Use of high-flownasal cannula for acute dyspnea and hypoxemia in the emergencydepartment. Respir Care 2015; 60: 1377–1382

  21. Jones PG, Kamona S, Doran O, et al. Randomized controlled trialof humidified high-flow nasal oxygen for acute respiratory distressin the emergency department: the HOT-ER Study. Respir Care2016; 61: 291–299.

  22. Makdee O, Monsomboon A, Surabenjawong U, et al. High-flow nasal cannula versus conventional oxygen therapy inemergency department patients with cardiogenic pulmonaryedema: a randomized controlled trial. Ann Emerg Med 2017;70: 465–472.

  23. Azoulay E, Lemiale V, Mokart D, et al. Effect of high-flow nasaloxygen vs standard oxygen on 28-day mortality in immunocompromisedpatients with acute respiratory failure: the HIGH randomizedclinical trial. JAMA 2018; 320: 2099–2107.

  24. Grieco DL, Menga LS, Eleuteri D, et al. Patient self-inflicted lunginjury: implications for acute hypoxemic respiratory failure andARDS patients on non-invasive support. Minerva Anestesiol 2019;85: 1014–1023.

  25. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannulafor acute hypoxemic respiratory failure in patients with COVID-19:systematic reviews of effectiveness and its risks of aerosolization,dispersion, and infection transmission. Can J Aneasth 2020; 67:1217–1248.

  26. Ferioli M, Cisternino C, Leo V, et al. Protecting healthcare workersfrom SARS-CoV-2 infection: practical indications. Eur Respir Rev2020; 29: 200068.

  27. Franco C, Facciolongo N, Tonelli R, et al. Feasibility and clinical impactof out-of-ICU noninvasive respiratory support in patients withCOVID-19-related pneumonia. Eur Respir J 2020; 56: 2002130.

  28. Junhai Z, Jing Y, Beibei C, Li L. The value of ROX index in predictingthe outcome of high flow nasal cannula: a systematic reviewand meta-analysis. Respir Res. 2022 Feb 17;23(1):33. doi:10.1186/s12931-022-01951-9.

  29. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructivepulmonary disease. N Engl J Med. 2019;381(13):1257–66.

  30. MacIntyre NR. Pathophysiology of acute respiratory failurein chronic obstructive pulmonary disease. Respir Care.2008;53(6):649–57.

  31. Piper AJ, Grunstein RR. Obesity hypoventilation syndrome:mechanisms and management. Am J Respir Crit Care Med.2011;183(3):292–8.

  32. Ergan B, Oczkowski S, Rochwerg B, et al. European RespiratorySociety guidelines on noninvasive respiratory support in acute respiratoryfailure. Eur Respir J. 2021;58(6):2101149.

  33. Spicuzza L, Schisano M: High-flow nasal cannula oxygen therapyas an emerging option for respiratory failure: the present and thefuture. Ther Adv Chronic Dis. 2020, 13:2040622320920106

  34. Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G,et al. Physiologic effects of high-flow nasal cannula in acutehypoxemic respiratory failure. Am J Respir Crit Care Med.2017;195(9):1207-1215. doi:10.1164/rccm.201605-0916OC

  35. Parke R, McGuinness S, Eccleston M: Nasal high-flow therapydelivers low level positive airway pressure . Br J Anaesth. 2009,103:886-890.




2020     |     www.medigraphic.com